Neuroleptic malignant syndrome
Jump to navigation
Jump to search
Neuroleptic malignant syndrome is "potentially fatal syndrome associated primarily with the use of neuroleptic agents (see antipsychotic agents) which are in turn associated with dopaminergic receptor blockade in the basal ganglia and hypothalamus, and sympathetic dysregulation. Clinical features include diffuse muscle rigidity; tremor; high fever; diaphoresis; labile blood pressure; cognitive dysfunction; and autonomic disturbances. Serum CPK level elevation and a leukocytosis may also be present."[1][2][3]
Blockade of the D2 receptors, which may be predisposed by genetic polymorphisms of the allele, may cause neuroleptic malignant syndrome.[4]
References
- ↑ Anonymous (2024), Neuroleptic malignant syndrome (English). Medical Subject Headings. U.S. National Library of Medicine.
- ↑ Ropper, Allan H.; Adams, Raymond Delacy; Victor, Maurice (1997). Principles of Neurology. New York: McGraw-Hill, Health Professions Division, 1199. ISBN 0-07-067439-6.
- ↑ Pelonero AL, Levenson JL, Pandurangi AK (1998). "Neuroleptic malignant syndrome: a review". Psychiatr Serv 49 (9): 1163-72. PMID 9735957. [e]
- ↑ Kishida I, Kawanishi C, Furuno T, Kato D, Ishigami T, Kosaka K (2004). "Association in Japanese patients between neuroleptic malignant syndrome and functional polymorphisms of the dopamine D(2) receptor gene". Mol. Psychiatry 9 (3): 293-8. DOI:10.1038/sj.mp.4001422. PMID 15094790. Research Blogging.